Abstracts tagged "Disease Activity"

Abstract Number: 0721 • ACR Convergence 2020
Validation of New Antirheumatic Drug Use as a Proxy for Increased JIA Disease Activity
Avinash Gabbeta¹, Evan Mulvihill², Timothy Beukelman³, James Lewis⁴, Carlos Rose⁵, Brian Strom⁶ and Daniel Horton⁷, ¹St. Christopher's Hospital for Children, Philadelphia, PA, ²Nemours A.I. duPont Hospital for Children, Wilmington, DE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Nemours A.I. duPont Hospital for Children, Wilmingon, DE, ⁶Rutgers University, Newark, NJ, ⁷Rutgers University, New Brunswick, NJ
Background/Purpose: Administrative claims databases are valuable tools for studying treatment effects in large JIA populations but do not contain direct measures of disease activity, limiting…
Abstract Number: 0829 • ACR Convergence 2020
International Comparison of Japanese and US Cross Country Utilization of RA Medications
Hisashi Yamanaka¹, Mitsumasa Kishimoto², Kazuhisa Nakano³, Kenta Misaki⁴, Yuji Yamanishi⁵, Hiroaki Dobashi⁶, Masamitsu Natsumeda⁷, Toshiaki Miyamoto⁸, Koichi Amano⁹, Akira Sagawa¹⁰, Norihiko Koido¹¹, Corrona Japan Consortium¹², Leslie Harrold¹³, Tin-chi Lin¹³, Jeffrey Greenberg¹⁴ and Yoshiya Tanaka³, ¹Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ²Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Kitaharima Medical Center, Ono, Japan, ⁵Hiroshima Rheumatology Clinic, Hiroshima, Japan, ⁶Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ⁷Mabi Memorial Hospital, Kurashiki, Japan, ⁸Seirei Hamamatsu General Hospital, Hamamatsu, Japan, ⁹Saitama Medical Center, Kawagoe, Japan, ¹⁰Sagawa Akira Rheumatology Clinic, Sapporo, Japan, ¹¹Kawasaki RA & IM Clinic, Kawasaki, Japan, ¹²Corrona Japan Consortium, Japan, Japan, ¹³Corrona, LLC, Waltham, MA, ¹⁴Corrona, LLC and NYU School of Medicine, Waltham, MA
Background/Purpose: Little is known regarding differences in DMARD utilization across countries. A better understanding is needed to contextualize findings from different countries.1 Using the same…
Abstract Number: 0989 • ACR Convergence 2020
Withdrawal of MMF Is Safe in Quiescent Renal and Non-Renal SLE: Results from a Multi-Center Randomized Trial
Eliza Chakravarty¹, Tammy Utset², Diane Kamen³, Gabriel Contreras⁴, W. Joseph McCune⁵, Kenneth Kalunian⁶, Cynthia Aranow⁷, Megan Clowse⁸, Elena Massarotti⁹, Ellen Goldmuntz¹⁰, Jessica Springer¹⁰, Lynette Keyes-Elstein¹¹, Bill Barry¹¹, Ashley Pinckney¹¹ and Judith James¹², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Chicago, Chicago, IN, ³Medical University of South Carolina, Charleston, SC, ⁴University of Miami Miller School of Medicine, Miami, ⁵University of Michigan, Ann Arbor, MI, ⁶University of California San Diego, La Jolla, CA, ⁷Feinstein Institutes for Medical Research, Manhasset, NY, ⁸Duke University, Chapel Hill, NC, ⁹Brigham and Women's hospital, Boston, MA, ¹⁰NIH/NIAID, Rockville, MD, ¹¹Rho, Durham, NC, ¹²Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Mycophenolate Mofetil (MMF) is standard of care therapy for long term treatment of lupus nephritis and other manifestations of SLE. However, it is associated…
Abstract Number: 1232 • ACR Convergence 2020
Association of Low Hemoglobin with Efficacy and Patient-reported Outcomes in Three Phase III Studies of Sarilumab (TARGET, MOBILITY and MONARCH)
Andrea Rubbert Roth¹, Daniel Furst*², Stefano Fiore³, Amy Praestgaard⁴, Vivian Bykerk⁵, Clifton Bingham III⁶ and Christina Charles-Schoeman⁷, ¹Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, ²Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ³Sanofi, Bridgewater, NJ, ⁴Sanofi, Cambridge, MA, ⁵Hospital for Special Surgery, New York, NY, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Anemia is a common comorbidity in patients (pts) with RA, and changes in hemoglobin (Hb) levels are associated with changes in inflammatory disease activity. Since…
Abstract Number: 1393 • ACR Convergence 2020
Systemic Sclerosis: Subclinical Aterosclerosis and Morbimortality
Miriam Retuerto¹, Jose Luis Rosales², Maria Martin¹, Beatriz Joven¹ and Patricia E Carreira¹, ¹Hospital universitario 12 de octubre, Madrid, Spain, ²Hospiten Rambla, Santa Cruz de Tenerife, Spain
Background/Purpose: Rheumatic diseases are associated with accelerated atherosclerosis, and an increase in cardiovascular morbidity and mortality. This process is mediated by classic cardiovascular risk factors…
Abstract Number: 1724 • ACR Convergence 2020
A Feasible and Efficient Approach to Implementing Rheumatoid Arthritis Disease Activity Measure in a Busy Rheumatology Clinic: A Quality Improvement Project
Ali H.Ali¹, Amani Elghafri², Mosaab Mohameden³, Mandeep Sidhu² and Candice Reyes Yuvienco⁴, ¹University of California San Francisco Fresno, Fresno, CA, ²University of California San Francisco Fresno, Fresno, ³University of Cincinnati, Cincinnati, OH, ⁴University of California San Francisco Fresno, Clovis, CA
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has witnessed a substantial change over last the 20 years, with disease remission becoming an achievable goal. Treat-to-target…
Abstract Number: 1818 • ACR Convergence 2020
IgG and IgA Autoantibodies Against L1 ORF1p Expressed in Granulocytes Correlate with Granulocyte Consumption and Disease Activity in Pediatric Systemic Lupus Erythematosus
Kennedy Ukadike¹, Kathryn Ni¹, Victoria Carter¹, Martin Taylor², John LaCava³, Lauren Pachman⁴, Xiaoxing Wang¹, Mary Eckert⁵, Anne Stevens¹, Christian Lood¹ and Tomas Mustelin¹, ¹University of Washington, Seattle, WA, ²Massachusetts General Hospital, Boston, MA, ³Rockefeller University, New York, NY, ⁴Department of Pediatrics, Northwestern University Feinberg School of Medicine; The Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Rheumatology; The CureJM Center of Excellence in Juvenile Myositis Research and Care, The Stanley Manne Children's Research Center of Chicago, Lake Forest, IL, ⁵Seattle Children's Hospital, Seattle, WA
Background/Purpose: To quantitate autoantibodies against the RNA-binding p40 (ORF1p) protein encoded by the L1 retroelement, expression of p40 itself, and markers of neutrophil death in…
Abstract Number: 2031 • ACR Convergence 2020
Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis
Augusta Ortolan¹, Victoria Navarro-Compán², Alexandre Sepriano³, Robert Landewé⁴, Désirée van der Heijde⁵ and Sofia Ramiro⁶, ¹Leiden University Medical Center, Padova, Italy, ²Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ³Leiden University Medical Center, Portela Loures, Portugal, ⁴Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Several disease activity response and status criteria are used to assess treatment efficacy in RCTs in axial spondyloarthritis (axSpA). Response criteria include: the Assessment…
Abstract Number: 033 • 2020 Pediatric Rheumatology Symposium
Parental Adverse Childhood Experience (ACE) Exposure Is Predictive of Active Lupus in Pediatric Patients
Michael Nelson¹, Nancy Correa ², Ashley Butler ¹, Marietta De Guzman ³, Bethanie Van Horne ¹ and Christopher Greeley ¹, ¹Baylor College of Medicine, Houston, ²Texas Children's Hospital, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Adverse Childhood Experiences (ACEs) have been recognized for more than two decades as risk factors for poor health outcomes in adults. Nevertheless, the impact…
Abstract Number: 071 • 2020 Pediatric Rheumatology Symposium
Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus
Lauren Ambler¹, Rula Issa ², Stephanie Pan ² and Rebecca Trachtman ², ¹Mount Sinai Hospital, New York, ²Icahn School of Medicine at Mount Sinai, New York
Background/Purpose: It has been established that pediatric Systemic Lupus Erythematous (pSLE) is associated with lower health-related quality of life (HRQOL); however, there are few studies…
Abstract Number: 078 • 2020 Pediatric Rheumatology Symposium
Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma
Suzanne Li¹, Mara Becker ², Sandy Hong ³, Polly Ferguson ⁴, Themba Nyrienda ⁵, Tracy Andrews ⁶, Katie Stewart ⁷, C. Egla Rabinovich ⁸, Robert Fuhlbrigge ⁹, Thomas Mason ¹⁰, Elena Pope ¹¹, Maria Ibarra ¹², Fatma Dedeoglu ¹³, Gloria Higgins ¹⁴, Ronald Laxer ¹⁵, Marilynn Punaro ¹⁶ and Kathryn Torok ¹⁷ for the CARRA investigators, ¹Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, ³University of Iowa Stead Family Children's Hospital, Iowa City, ⁴University of Iowa Carver College of Medicine, Iowa City, ⁵Hackensack Univesity Medical Center, Hackensack, ⁶Rutgers University, Newark, ⁷UT Southwestern, Dallas, ⁸Duke University Hospital, Durham, ⁹University of Colorado, Aurora, ¹⁰Rochester, ¹¹Hospital For Sick Kids, Toronto, Canada, ¹²Children's Mercy Kansas City, Kansas City, ¹³Boston Children's Hospital, Boston, ¹⁴Nationwide Childrens Hospital/ The Ohio State University, Columbus, ¹⁵The Hospital for Sick Children and University of Toronto, Toronto, Canada, ¹⁶Dallas, Texas, ¹⁷Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh
Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease. Treatment is directed towards controlling disease activity to minimize risk for functional impairment…
Abstract Number: 128 • 2020 Pediatric Rheumatology Symposium
Predictors of Moderate/High Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Emily Smitherman¹, Rouba Chahine ¹, Timothy Beukelman ¹, Andrea Knight ², AKM Fazlur Rahman ¹, Mary Beth Son ³, Jeffrey R Curtis ⁴ and Aimee Hersh ⁵ for the CARRA investigators, ¹University of Alabama at Birmingham, Birmingham, ²SickKids Research Institute, Toronto, Canada, ³Boston Children's Hospital, Boston, Massachusetts, ⁴University of Alabama at Birmingham, Hoover, ⁵University of Utah Primary Children's Hospital, Salt Lake City
Background/Purpose: Substantial risk of early morbidity and mortality exists for patients with childhood-onset systemic lupus erythematosus (cSLE), but there are limited studies identifying predictors of…
Abstract Number: 139 • 2020 Pediatric Rheumatology Symposium
Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study
Mia Glerup¹, Ellen D Arnstad ², Veronika Rypdal ³, Suvi Peltoniemi ⁴, Kristiina Aalto ⁵, Marite Rygg ⁶, Susan Nielsen ⁷, Anders Fasth ⁸, Lillemor Berntson ⁹, Ellen Nordal ³ and Troels Herlin ¹⁰, ¹Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ²Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, and Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Tromheim, Norway, ³Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, ⁴Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., Helsinki, Finland, ⁵Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, ⁶Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, ⁷Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhagen, Denmark, ⁸Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, ⁹Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, ¹⁰Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark
Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission…
Abstract Number: L17 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
Eric Morand¹, Richard Furie ², Yoshiya Tanaka ³, Ian Bruce ⁴, Anca Askanase ⁵, Christophe Richez ⁶, Sang-Cheol Bae ⁷, Philip Brohawn ⁸, Lilia Pineda ⁹, Anna Berglind ¹⁰ and Raj Tummala ⁹, ¹Monash University, Melbourne, Victoria, Australia, ²Zucker School of Medicine at Hofstra/Northwell, New York, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁵Columbia University, New York, ⁶CHU de Bordeaux-GH Pellegrin, Bordeaux, France, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸Former employee of AstraZeneca, Gaithersburg, Maryland, ⁹AstraZeneca, Gaithersburg, Maryland, ¹⁰AstraZeneca, Gothenburg, Sweden
Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…
Abstract Number: 473 • 2019 ACR/ARP Annual Meeting
RA Presents in Disease Patterns Impacting Treatment Response
Kathryne Marks¹, Dana Symons ², Cynthia Crowson ³, Pamela Sinicrope ⁴ and Kelly O'Neill ⁵, ¹Rosalind Franklin University of Medicine and Science, Gurnee, IL, ²Rheumatoid Patient Foundation, Inc., Rockford, MI, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, MN, ⁵Rheumatoid Patient Foundation, Inc., Winter Springs, FL
Background/Purpose: Despite significant research on rheumatoid arthritis (RA), disease courses have not been clearly described. Like systemic lupus erythematosus and multiple sclerosis, RA displays a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].